Key Developments: BTG PLC (BTG.L)

BTG.L on London Stock Exchange

22 May 2015
Change (% chg)

4.50p (+0.62%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

BTG plc announces REVOLENS Study Results
Tuesday, 19 May 2015 02:02am EDT 

BTG plc:Presents top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint.Says results show the PneumRx endobronchial coil is superior to the standard of care for improving exercise capacity in patients with severe emphysema at 6 months as measured by the 6 minute walk test.  Full Article

BTG Plc raises FY 2015 revenue guidance
Thursday, 5 Feb 2015 10:04am EST 

BTG Plc:Says that FY 2015 revenue to be in range 345 - 360 million pounds; previous guidance was 330 - 345 million pounds.New guidance reflects acquisition of PneumRx Inc, which completed on Jan. 7, and reversal of adverse foreign exchange impact reported for six months to Sept. 30, 2014.FY 2015 revenue of 353 million pounds - Thomson Reuters I/B/E/S.  Full Article

BTG announces completion of the acquisition of PneumRx Inc
Thursday, 8 Jan 2015 02:00am EST 

BTG Plc:Completes the acquisition of PneumRx Inc, a growing interventional pulmonology business.  Full Article

BTG plc announces proposed placing of new ordinary shares
Thursday, 4 Dec 2014 02:01am EST 

BTG plc:Announces its intention to conduct a placing of new ordinary shares in the company to institutional investors to raise about 150 mln Pounds (the Gross Proceeds), which represents about 5 pct of the company's market capitalisation based on Dec. 30 closing share price.Placing is being conducted through an accelerated bookbuilding process.Deutsche Bank AG, London Branch ( Deutsche Bank ) and J.P. Morgan Securities plc, which conducts its UK investment banking activities as J.P. Morgan Cazenove ( J.P. Morgan Cazenove) , are acting as Joint Bookrunners in connection with the Placing.  Full Article

BTG plc announces acquisition of PneumRx Inc
Thursday, 4 Dec 2014 02:01am EST 

BTG plc:Enters into an agreement to acquire PneumRx Inc on a debt free cash free basis for an initial cash consideration of $230 mln (about 1.471 bln pounds ) and up to US$245 million (about 1.561 bln pounds) in performance-related future milestone payments.The acquisition will be funded in part by a cashbox placing with gross proceeds of about 150 mln pounds, representing about 5 pct of the company's market capitalisation based on Dec. 3 closing share price.Closing of the acquisition is expected to be received in early Jan. 2015.  Full Article

BTG Plc sees FY 2015 revenues to be at top end of prior range
Tuesday, 11 Nov 2014 02:00am EST 

BTG Plc:Expects FY 2015 revenues to be around the top end of the company guidance range of 330 million pound to 345 million pounds, despite adverse foreign exchange impacts.  Full Article

BTG Plc reaches settlement regarding CroFab patent litigation
Friday, 10 Oct 2014 07:00am EDT 

BTG Plc:Says it has settled its United States patent infringement complaint against Instituto Bioclon (Bioclon) of Mexico and Rare Disease Therapeutics, Inc. (RDT) of Nashville, Tennessee.The case was filed by BTG with International Trade Commission in Oct. 2013 based upon unlawful and unauthorised importation and sale into US of certain crotalid antivenom pharmaceutical compositions that infringe one or more claims of BTG's US Patent No. 8,048,414 (the 414 patent).Under terms of agreement, BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG's 414 patent from Oct. 2018, subject to Bioclon receiving regulatory approval for its antivenom product.BTG will receive single-digit royalty on sales of any Bioclon product relying on 414 patent until end of the exclusivity period in 2028.In addition, Bioclon will withdraw its legal challenge to validity of 414 patent.BTG has agreed to reimburse Bioclon $6 mln for its legal fees and costs incurred.  Full Article

BTG plc sees FY 2015 revenue at top end of prior guidance range
Monday, 6 Oct 2014 02:00am EDT 

BTG plc:Expects FY 2015 revenues to be around the top end of its guidance range of 330 mln pounds to 345 mln pounds.FY 2015 revenue of 343 mln pounds - Thomson Reuters I/B/E/S.  Full Article

SciClone Pharmaceuticals Inc and BTG announce that DC Bead has been approved by China Food and Drug Administration
Thursday, 28 Aug 2014 02:00am EDT 

SciClone Pharmaceuticals Inc:Announced that China Food and Drug Administration has approved registration of DC Bead for embolization of malignant hypervascularized tumors.BTG and SciClone previously entered into an agreement granting SciClone exclusive licensing and distribution rights to DC Bead in China.Under agreement, SciClone will purchase product from BTG at specified price for sale in China.Commercial launch plans are underway.  Full Article

BTG PLC reaffirms FY 2015 revenue guidance
Wednesday, 16 Jul 2014 02:00am EDT 

BTG PLC:Expects FY 2015 revenue to be in 330-345 mln pounds range as previously guided, despite recent weakening of the US dollar versus sterling.FY 2015 revenue of 342 mln pounds - Thomson Reuters I/B/E/S.  Full Article

Britain's BTG sees two-year build-up for varicose vein product

LONDON, May 19 - British pharmaceutical company BTG said its full-year profit was dampened by investment in new products, including its Varithena varicose veins treatment in the United States.

Search Stocks